UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 230

Sortiert nach

Amyloid‐ß‐directed immunotherapy for Alzheimer's disease

Journal of internal medicine, 2014-03, Vol.275 (3), p.284-295

2014

Link zum Volltext

Verfügbarkeit prüfen

Commentary: Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force

The journal of prevention of Alzheimer's disease, 2019, Vol.6 (3), p.180-181

Siemers, E

2019

Link zum Volltext

Verfügbarkeit prüfen

Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease

Neurology, 2006-02, Vol.66 (4), p.602

2006

Link zum Volltext

Verfügbarkeit prüfen

Designing clinical trials for early (pre-dementia) Alzheimer’s disease: Determining the appropriate population for treatment

The Journal of nutrition, health & aging, 2011, Vol.15 (1), p.22-24

Siemers, E.

2011

Link zum Volltext

Verfügbarkeit prüfen

Practice effects and the use of alternate forms in serial neuropsychological testing

Archives of clinical neuropsychology, 2005-06, Vol.20 (4), p.517-529

2005

Link zum Volltext

Verfügbarkeit prüfen

The Ups and Downs of Amyloid in Alzheimer’s

The journal of prevention of Alzheimer's disease, 2022-01, Vol.9 (1), p.92-95

2022

Link zum Volltext

Verfügbarkeit prüfen

How can we recognize “disease modification” effects?

The Journal of nutrition, health & aging, 2009-04, Vol.13 (4), p.341-343

Siemers, E. R.

2009

Link zum Volltext

Verfügbarkeit prüfen

ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aß Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan

The journal of prevention of Alzheimer's disease, 2023, Vol.10 (1), p.19

2023

Link zum Volltext

Verfügbarkeit prüfen

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

The New England journal of medicine, 2018-01, Vol.378 (4), p.321-330

2018

Link zum Volltext

Verfügbarkeit prüfen

DESIGNING CLINICAL TRIALS FOR EARLY (PRE-DEMENTIA) ALZHEIMER'S DISEASE: DETERMINING THE APPROPRIATE POPULATION FOR TREATMENT

The Journal of nutrition, health & aging, 2011, Vol.15 (1), p.22-24

SIEMERS, E

2011

Link zum Volltext

Verfügbarkeit prüfen

Amyloid-beta-directed immunotherapy for Alzheimer's disease

Journal of internal medicine, 2014-03, Vol.275 (3), p.284

2014

Link zum Volltext

Verfügbarkeit prüfen

Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force

The journal of prevention of Alzheimer's disease, 2019, Vol.6 (3), p.180-181

Siemers, E.

2019

Link zum Volltext

Verfügbarkeit prüfen

Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer’s Disease in EXPEDITION 3

The journal of prevention of Alzheimer's disease, 2018, Vol.5 (3), p.184-187

2018

Link zum Volltext

Verfügbarkeit prüfen

Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer’s Disease

The journal of prevention of Alzheimer's disease, 2018, Vol.5 (1), p.8-14

2018

Link zum Volltext

Verfügbarkeit prüfen

THE INFLUENCE OF MATRIX TYPE, DIURNAL RHYTHM AND SAMPLE COLLECTION AND PROCESSING ON THE MEASUREMENT OF PLASMA β-AMYLOID ISOFORMS USING THE INNO-BIA PLASMA AB FORMS MULTIPLEX ASSAY

The Journal of nutrition, health & aging, 2009, Vol.13 (3), p.220-225

2009

Link zum Volltext

Verfügbarkeit prüfen

Subtle changes among presymptomatic carriers of the Huntington's disease gene

Journal of neurology, neurosurgery and psychiatry, 2000-12, Vol.69 (6), p.773-779

2000

Link zum Volltext

Verfügbarkeit prüfen

Risky decision making in Huntington's disease

Journal of the International Neuropsychological Society, 2001-01, Vol.7 (1), p.92-101

2001

Link zum Volltext

Verfügbarkeit prüfen

Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A

Movement disorders, 2000-01, Vol.15 (1), p.150-153

2000

Link zum Volltext

Verfügbarkeit prüfen

Designing clinical trials for early (Pre-Dementia) Alzheimer’s disease: Determining the appropriate population for treatment

The Journal of nutrition, health & aging, 2010-05

Siemers, E.

2010

Link zum Volltext

Verfügbarkeit prüfen

ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aβ Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan

The journal of prevention of Alzheimer's disease, 2023, Vol.10 (1), p.19-24

2023

Link zum Volltext

Verfügbarkeit prüfen

Anxiety and motor performance in parkinson's disease

Movement disorders, 1993, Vol.8 (4), p.501-506

1993

Link zum Volltext

Verfügbarkeit prüfen

Report of the task force on designing clinical trials in early (predementia) AD

Neurology, 2011-01, Vol.76 (3), p.280

2011

Link zum Volltext

Verfügbarkeit prüfen

The role of biomarkers in clinical trials for Alzheimer disease

Alzheimer disease and associated disorders, 2006, Vol.20 (1), p.6-15

2006

Link zum Volltext

Verfügbarkeit prüfen

PET imaging of the pre-synaptic dopamine uptake sites in rapid-onset dystonia-parkinsonism (RDP)

Movement disorders, 1999-01, Vol.14 (1), p.132-137

1999

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 230

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(187)
Mit Volltextzugriff
(193)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(210)
Japanisch
(25)
Deutsch
(21)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(129)
Life Sciences & Biomedicine
(101)
Humans
(96)
Biological And Medical Sciences
(58)
Male
(49)
Medical Sciences
(49)
Neurology
(46)
Neurosciences & Neurology
(46)
Female
(45)
Clinical Neurology
(42)
Middle Aged
(35)
Adult
(32)
Animals
(25)
Aged
(24)
Physical Sciences
(23)
Alzheimer's Disease
(16)
Pharmacology. Drug Treatments
(15)
Alzheimer Disease - Drug Therapy
(14)
Fundamental And Applied Biological Sciences. Psychology
(14)
Neurosciences
(14)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Amyloid‐ß‐directed immunotherapy for Alzheimer's disease

Commentary: Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force

Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease

Designing clinical trials for early (pre-dementia) Alzheimer’s disease: Determining the appropriate population for treatment

Practice effects and the use of alternate forms in serial neuropsychological testing

The Ups and Downs of Amyloid in Alzheimer’s

How can we recognize “disease modification” effects?

ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aß Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

DESIGNING CLINICAL TRIALS FOR EARLY (PRE-DEMENTIA) ALZHEIMER'S DISEASE: DETERMINING THE APPROPRIATE POPULATION FOR TREATMENT

Amyloid-beta-directed immunotherapy for Alzheimer's disease

Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force

Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer’s Disease in EXPEDITION 3

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer’s Disease

THE INFLUENCE OF MATRIX TYPE, DIURNAL RHYTHM AND SAMPLE COLLECTION AND PROCESSING ON THE MEASUREMENT OF PLASMA β-AMYLOID ISOFORMS USING THE INNO-BIA PLASMA AB FORMS MULTIPLEX ASSAY

Subtle changes among presymptomatic carriers of the Huntington's disease gene

Risky decision making in Huntington's disease

Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A

Designing clinical trials for early (Pre-Dementia) Alzheimer’s disease: Determining the appropriate population for treatment

ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aβ Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan

Anxiety and motor performance in parkinson's disease

Report of the task force on designing clinical trials in early (predementia) AD

The role of biomarkers in clinical trials for Alzheimer disease

PET imaging of the pre-synaptic dopamine uptake sites in rapid-onset dystonia-parkinsonism (RDP)

Suchergebnisse filtern